Veradermics, Inc
Veradermics Inc (MANE) fell 4.8% to $97.9, hitting a low of $93.81, due to insider selling and dilution concerns. CEO and directors sold significant shares, and the company reported a wider Q2 2026 loss of $23.5M. Analysts maintain bullish targets, but broader market weakness also pressured the stock.
Veradermics Inc (MANE) shares dropped 4.8% on Monday after Montanova Capital sold 750,000 shares at $107.25 each, as disclosed in an SEC filing. Montanova Capital remains a significant shareholder, holding 3.1 million shares indirectly. David Friedman, a Montanova Capital executive, serves on Veradermics' board.
MONTANOVA CAPITAL, LLC sold 750,000 indirectly-held shares of Veradermics, Inc (MANE) at $107.25 ($80.44M total) across 2 trades on 2026-08-19. Filed jointly with Cowen Aaron, Averill Master Fund, Ltd. (Director) and Averill Madison Master Fund, Ltd. (Director).
Over the past 7 days, alphai's AI scored 2 news stories mentioning MANE (Veradermics, Inc). Coverage has skewed bearish: 0 bullish, 0 neutral, and 2 bearish.
Recent MANE coverage spans insider activity, market movers and earnings.
In the last 30 days, MANE insiders filed 15 SEC Form 4 transactions — no purchases and 15 sales ($103.1M). The most active reporter was Durso Timothy August, Chief Technical Officer, with 5 filings. 67% of those filings were made under pre-arranged Rule 10b5-1 plans.
Bearish pressure from insider liquidation and increased share supply.
The insider sale suggests negative sentiment and potential further downside.
Significant insider sell may signal lack of confidence, pressure on stock price.
Insider selling is disclosed, but the presence of a pre-arranged 10b5-1 plan reduces signal strength versus discretionary selling.
The filing is a disclosed insider sale, not a fundamental update, but it can still affect near-term sentiment and positioning.
alphai scores every news story that mentions MANE with an AI model for sentiment and relevance, and aggregates insider trades from Veradermics, Inc's SEC EDGAR Form 4 filings. Figures refresh continuously.
Veradermics Inc (MANE) fell 4.8% to $97.9, hitting a low of $93.81, due to insider selling and dilution concerns. CEO and directors sold significant shares, and the company reported a wider Q2 2026 loss of $23.5M. Analysts maintain bullish targets, but broader market weakness also pressured the stock.
2 min readVeradermics Inc (MANE) shares dropped 4.8% on Monday after Montanova Capital sold 750,000 shares at $107.25 each, as disclosed in an SEC filing. Montanova Capital remains a significant shareholder, holding 3.1 million shares indirectly. David Friedman, a Montanova Capital executive, serves on Veradermics' board.
2 min readMONTANOVA CAPITAL, LLC sold 750,000 indirectly-held shares of Veradermics, Inc (MANE) at $107.25 ($80.44M total) across 2 trades on 2026-08-19. Filed jointly with Cowen Aaron, Averill Master Fund, Ltd. (Director) and Averill Madison Master Fund, Ltd. (Director).
1 min readDurso Timothy August (Chief Technical Officer) sold 43,500 shares of Veradermics, Inc (MANE) at an average of $107.82 ($106.71–$111.28, $4.69M total) across 5 trades on 2026-08-17 under a Rule 10b5-1 trading plan.
2 min readWaldman Reid Alexander (Chief Executive Officer) sold 67,500 shares of Veradermics, Inc (MANE) at an average of $107.86 ($106.72–$111.28, $7.28M total) across 5 trades on 2026-08-17 under a Rule 10b5-1 trading plan.
2 min readCHILDS JOHN W sold 100,000 indirectly-held shares of Veradermics, Inc (MANE) at an average of $107.12 ($106.14–$108.24, $10.71M total) across 3 trades on 2026-08-12.
2 min readVeradermics, Inc (MANE) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Veradermics Reports Second Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress Positive topline results from open-label Phase 2 Study ‘207’ evaluating VDPHL01 in female pattern hair loss demonstrated rapid onset and consistent hair gr
6 min readInvesting.com reports Friday’s market weakness, with Nasdaq down about 1% and stocks set for a weekly loss. It lists major movers including Micron Tech (MU) up 3.66%, Oracle (ORCL) up 2.7%, and Coca-Cola (KO) down 4.66% after fairlife suspends US production following a cyberattack. Other cited moves include Applied Materials (AMAT) down 4.3% and SpaceX (SPCX) down 4.07%.
4 min readBiotech stocks rose Wednesday. Apollomics (APLM) jumped 22% after Nasdaq closed its MVLS compliance issue. Iovance (IOVA) gained 21% ahead of Q2 results; AVITA Medical (RCEL) rose 18% before Aug. 6 earnings; Annexon (ANNX) climbed 17% ahead of ARCHER II updates. Veradermics (MANE) gained 12% on Phase 2 hair-loss topline results.
7 min readVeradermics (NYSE:MANE) reported positive Phase 2 results for VDPHL01 in women with female pattern hair loss. In a 6-month study at 4.5 mg once daily or twice daily, hair count increased about 22.7 and 23.3 hairs/cm², respectively. By month six, 88.9% and 90% reported improved coverage, with no treatment-related serious adverse events. Shares were up 15.01% to $126.71.
4 min read
